JY 09
Alternative Names: Exendin-4Fc fusion protein - Beijing Dongfang Biotech; JY-09Latest Information Update: 27 Aug 2024
At a glance
- Originator Beijing Dongfang Biotech
- Class Antihyperglycaemics; Antihyperlipidaemics; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 27 Aug 2024 Phase-III clinical trials in Type 2 diabetes mellitus in China (SC) (NCT06254014)
- 17 Jul 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Treatment-experienced) in China (SC) (NCT06257966)
- 15 Apr 2024 Beijing Dongfang Biotech completes a phase I trial in Type 2 diabetes mellitus (Combination therapy) in China (SC) (NCT06247748)